Human Vaccines & Immunotherapeutics (Sep 2021)

Is a single COVID-19 vaccine dose enough in convalescents ?

  • Daniele Focosi,
  • Andreina Baj,
  • Fabrizio Maggi

DOI
https://doi.org/10.1080/21645515.2021.1917238
Journal volume & issue
Vol. 17, no. 9
pp. 2959 – 2961

Abstract

Read online

SARS-CoV-2 has infected more than 122 million persons worldwide. Most currently licensed COVID-19 vaccines require a two-dose course and many health systems are on a shortage of doses. The requirement for boosting the response after priming with the first dose is uncertain in convalescents already primed by the natural infection. Mounting evidences suggest that, after a single vaccine dose, convalescents develop antibody (total and neutralizing) levels similar to the ones measured in naïve vaccinees after the full two-dose course. While concerns remain on the equivalent duration of such response, optimizing vaccine delivery to convalescents seems effective and could accelerate achievement of herd immunity.

Keywords